Eli Lilly's GLP-1 pill Foundayo showed significant improvement in obstructive sleep apnea in Phase 3 trials, with FDA submission planned by end of 2026. Sales jumped from $98 million in Q2 to $184 million in Q3, driving a 28% stock rise this year. The company targets a $1,800 share price in 2027, supported by growth in diabetes treatment, global expansion, and new drug candidates. Challenges include price declines and one-time costs, but strong earnings growth and market potential underpin optimism.
Eli Lilly's stock price on Pluang reached USD 1,398.61 with a 3.29% increase as of Nov 09, 2026 23:41 WIB, reflecting strong investor interest. The company holds a substantial market cap of $1.21 trillion and an enterprise value of $1.25 trillion, underscoring its significant presence in the health sector. This trading activity aligns with the news of its GLP-1 pill Foundayo's promising trial results and planned FDA submission, highlighting continued growth potential.
Hims & Hers Health has struck a deal with Eli Lilly allowing patients to buy Lilly's GLP-1 medications, including the popular Zepbound injection and Foundayo pill, directly through Hims & Hers' telehealth platform. Previously, patients had to use Lil...
Hims & Hers Health announced a partnership with Eli Lilly to offer Eli Lilly's GLP-1 drugs through its platform, providing a significant boost to the company's stock. This agreement is seen as a much-needed positive development for Hims & Hers, poten...
ARK Invest, led by Cathie Wood, sold $12.8 million worth of Alphabet shares shortly after the stock experienced its worst trading day since its 2004 IPO, losing nearly half a trillion dollars in market value. The selloff followed Alphabet's Q3 earnin...
The recent U.S. midterm elections resulted in a Democratic 'Blue Wave,' with the party gaining control of both the House and Senate. This shift is expected to influence healthcare policy and funding, benefiting health insurers like UnitedHealth and C...
LifeMD has partnered with Eli Lilly to allow its affiliated pharmacy to dispense and ship Lilly's self-pay GLP-1 medications, Zepbound® and Foundayo®, directly to eligible patients across the U.S. Patients prescribed these medications by LifeMD provi...
